CClinicalTrials.gg
Not yet recruitingNCT07844785PMOS-FRUpdated Sep 28, 2026

Metabolic and Hormonal Parameters in Women With Polyendocrine Metabolic Ovarian Syndrome

An observational study in Polycystic Ovary Syndrome, Polycystic Ovary Syndrome (PCOS) Women and Fetuin-A, sponsored by Istinye University. Not yet recruiting. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Istinye University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a common endocrine and metabolic disorder associated with insulin resistance, hyperandrogenism, and an increased risk of long-term metabolic complications. Fetuin-A and resistin are adipokines implicated in insulin resistance and chronic inflammation and may serve as potential biomarkers for metabolic dysfunction in women with PMOS.

This prospective observational case-control study aims to compare serum and salivary Fetuin-A and resistin levels between women with PMOS and healthy controls. The study will evaluate the correlation between serum and salivary biomarker concentrations and investigate their associations with insulin resistance, lipid profile, and hormonal parameters. The findings may help determine whether salivary measurements can serve as reliable non-invasive biomarkers for the diagnosis and metabolic assessment of PMOS.

Read the detailed description

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a complex endocrine disorder characterized by reproductive, metabolic, and hormonal abnormalities. Insulin resistance, chronic low-grade inflammation, and hyperandrogenism play central roles in its pathophysiology. Identifying reliable and non-invasive biomarkers may improve early diagnosis, metabolic risk assessment, and long-term clinical follow-up.

Fetuin-A is a glycoprotein involved in insulin signaling and glucose metabolism, whereas resistin is a pro-inflammatory adipokine associated with insulin resistance and metabolic dysfunction. Previous studies evaluating serum concentrations of these biomarkers in women with PMOS have reported inconsistent findings, and little is known about whether salivary concentrations accurately reflect serum levels.

This prospective observational case-control study will enroll 80 women aged 18-35 years, including 40 women diagnosed with PMOS according to the Rotterdam criteria and 40 age-matched healthy controls. Fasting blood and unstimulated saliva samples will be collected simultaneously. Serum and salivary Fetuin-A and resistin concentrations will be measured using enzyme-linked immunosorbent assay (ELISA). Metabolic and hormonal parameters, including fasting glucose, fasting insulin, HbA1c, lipid profile, total testosterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), and the free androgen index (FAI), will also be evaluated.

The primary objective is to determine the correlation between serum and salivary Fetuin-A and resistin levels. Secondary objectives include evaluating associations between these biomarkers and insulin resistance, lipid profile, anthropometric measurements, and hormonal parameters, as well as assessing the potential utility of salivary biomarkers as non-invasive tools for the metabolic evaluation of women with PMOS.

02

Conditions studied

  • Polycystic Ovary Syndrome
  • Polycystic Ovary Syndrome (PCOS) Women
  • Fetuin-A
  • Serum Biomarkers
  • Insulin Resistance
03

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women aged 18-35 years with Polyendocrine Metabolic Ovarian Syndrome (PMOS) and age-matched healthy women recruited from the outpatient gynecology and endocrinology clinics of Istinye University. Participants will undergo clinical evaluation and fasting blood and unstimulated saliva collection for biochemical analyses.

Inclusion criteria

PMOS Group:

  • Female, aged 18-35 years
  • Diagnosis of Polyendocrine Metabolic Ovarian Syndrome (PMOS) according to the Rotterdam criteria
  • BMI \<30 kg/m²
  • Written informed consent

Healthy Control Group:

  • Female, aged 18-35 years
  • Regular menstrual cycles
  • No diagnosis of PMOS
  • BMI \<30 kg/m²
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Diabetes mellitus
  • Chronic kidney or liver disease
  • Thyroid dysfunction
  • Hyperprolactinemia
  • Cushing syndrome
  • Non-classic congenital adrenal hyperplasia
  • Use of hormonal contraceptives, anti-androgens, glucocorticoids, metformin, or insulin-sensitizing medications within the previous 3 months
  • Severe periodontal disease or active oral infection
04

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • PMOS Group

    Women aged 18 to 35 years diagnosed with Polyendocrine Metabolic Ovarian Syndrome according to the Rotterdam criteria. Participants will undergo clinical and anthropometric evaluation, and fasting serum and unstimulated saliva samples will be collected for Fetuin-A, resistin, metabolic, and hormonal measurements.

    Diagnostic Test: Blood and Saliva Biomarker Assessment

  • Healthy Control Group

    Women aged 18 to 35 years with regular menstrual cycles and without Polyendocrine Metabolic Ovarian Syndrome. Participants will undergo the same clinical, anthropometric, serum, and saliva assessments as the PMOS group.

    Diagnostic Test: Blood and Saliva Biomarker Assessment

Interventions

  • Diagnostic testBlood and Saliva Biomarker Assessment

    Participants will provide fasting venous blood and unstimulated saliva samples for measurement of Fetuin-A and resistin concentrations using enzyme-linked immunosorbent assay (ELISA). Metabolic and hormonal parameters, including fasting glucose, fasting insulin, HbA1c, lipid profile, total testosterone, sex hormone-binding globulin (SHBG), and dehydroepiandrosterone sulfate (DHEAS), will also be assessed. No therapeutic intervention will be administered.

05

What researchers measure

Primary outcomes

  1. Correlation Between Serum and Salivary Fetuin-A and Resistin Levels

    To determine the correlation between serum and salivary Fetuin-A and resistin concentrations in women with Polyendocrine Metabolic Ovarian Syndrome (PMOS) and healthy controls.

    Time frame: At baseline (Day 1)

Secondary outcomes

  1. Serum Fetuin-A Levels

    Comparison of serum Fetuin-A concentrations between women with PMOS and healthy controls.

    Time frame: Baseline

  2. Salivary Fetuin-A Levels

    Comparison of salivary Fetuin-A concentrations between women with PMOS and healthy controls

    Time frame: Baseline

  3. Serum Resistin Levels

    Comparison of serum resistin concentrations between women with PMOS and healthy controls.

    Time frame: Baseline

  4. Salivary Resistin Levels

    Comparison of salivary resistin concentrations between women with PMOS and healthy controls.

    Time frame: Baseline

  5. Correlation Between Fetuin-A and Resistin Concentrations and HOMA-IR

    Serum and salivary Fetuin-A and resistin concentrations measured by ELISA will be correlated with HOMA-IR. HOMA-IR will be calculated from fasting glucose and fasting insulin concentrations. Correlations will be assessed using Pearson or Spearman correlation coefficients, as appropriate.

    Time frame: Baseline

  6. Correlation Between Fetuin-A and Resistin Concentrations and SHBG Concentration

    Serum and salivary Fetuin-A and resistin concentrations measured by ELISA will be correlated with serum sex hormone-binding globulin (SHBG) concentration. Correlations will be assessed using Pearson or Spearman correlation coefficients, as appropriate.

    Time frame: Baseline

  7. Correlation of Fetuin-A and Resistin Concentrations With DHEAS Concentration

    Serum and salivary Fetuin-A and resistin concentrations measured by ELISA will be correlated with serum dehydroepiandrosterone sulfate (DHEAS) concentration. Correlations will be assessed using Pearson or Spearman correlation coefficients, as appropriate.

    Time frame: Baseline

  8. Correlation of Fetuin-A and Resistin Concentrations With Free Androgen Index

    Serum and salivary Fetuin-A and resistin concentrations measured by ELISA will be correlated with the Free Androgen Index (FAI), calculated as (total testosterone / SHBG) × 100. Correlations will be assessed using Pearson or Spearman correlation coefficients, as appropriate.

    Time frame: Baseline

  9. Correlation of Fetuin-A and Resistin Concentrations With Total Cholesterol Concentration

    Serum and salivary Fetuin-A and resistin concentrations measured by ELISA will be correlated with serum \[total cholesterol / LDL cholesterol / HDL cholesterol / triglyceride\] concentration. Correlations will be assessed using Pearson or Spearman correlation coefficients, as appropriate.

    Time frame: Baseline

  10. Correlation of Fetuin-A and Resistin Concentrations With LDL Cholesterol Concentration

    Serum and salivary Fetuin-A and resistin concentrations measured by ELISA will be correlated with serum \[total cholesterol / LDL cholesterol / HDL cholesterol / triglyceride\] concentration. Correlations will be assessed using Pearson or Spearman correlation coefficients, as appropriate.

    Time frame: Baseline

  11. Correlation of Fetuin-A and Resistin Concentrations With HDL Cholesterol Concentration

    Serum and salivary Fetuin-A and resistin concentrations measured by ELISA will be correlated with serum \[total cholesterol / LDL cholesterol / HDL cholesterol / triglyceride\] concentration. Correlations will be assessed using Pearson or Spearman correlation coefficients, as appropriate.

    Time frame: Baseline

  12. Correlation of Fetuin-A and Resistin Concentrations With Triglyceride Concentration

    Serum and salivary Fetuin-A and resistin concentrations measured by ELISA will be correlated with serum \[total cholesterol / LDL cholesterol / HDL cholesterol / triglyceride\] concentration. Correlations will be assessed using Pearson or Spearman correlation coefficients, as appropriate.

    Time frame: Baseline

  13. Correlation Between Fetuin-A and Resistin Concentrations and Total Testosterone Concentration

    Serum and salivary Fetuin-A and resistin concentrations measured by ELISA will be correlated with serum total testosterone concentration. Correlations will be assessed using Pearson or Spearman correlation coefficients, as appropriate.

    Time frame: Baseline

  14. Correlation Between Fetuin-A and Resistin Concentrations and DHEAS Concentration

    Serum and salivary Fetuin-A and resistin concentrations measured by ELISA will be correlated with serum dehydroepiandrosterone sulfate (DHEAS) concentration. Correlations will be assessed using Pearson or Spearman correlation coefficients, as appropriate.

    Time frame: Baseline

  15. Correlation Between Fetuin-A and Resistin Concentrations and Free Androgen Index

    Serum and salivary Fetuin-A and resistin concentrations measured by ELISA will be correlated with the Free Androgen Index (FAI), calculated as (total testosterone / SHBG) × 100. Correlations will be assessed using Pearson or Spearman correlation coefficients, as appropriate.

    Time frame: Baseline

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07844785
Lead sponsor
Istinye University
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Ayşe İrem GÖKÇEK Dr, Dr
Contact
ayse.gokcek@istinye.edu.tr
5356476880

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion